Cogent Biosciences, Inc.
corporate_fare Company Profile
Cogent Biosciences, Inc. (NASDAQ:COGT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 19 items for COGT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for COGT spans 10-Q, 8-K, DEF 14A, 144.
Recent high-impact activity:
- Cogent 10-Q: Q3 Loss Widens to $111.4M; $791.1M Cash Funds Operations Into Late 2028
- Cogent Q3 Loss Widens to $111M as Three FDA Decisions Loom
- FDA Accepts Cogent's Bezuclastinib NDA for Advanced Systemic Mastocytosis, Sets June 2027 Decision Date
- Cogent Biosciences Q2 loss widens to $96.4M; cash runway extends into 2028 ahead of key FDA decisions
- Cogent Biosciences Q2 2026: $96.4M Net Loss, $865.9M Pro Forma Cash, and PDUFA Dates Set for Bezuclastinib
Financial Snapshot
Short Interest & Short Volume
8.68 days to coverFINRA reported short interest of 17,416,118 shares in COGT as of the October 30, 2026 settlement, a 11.4% decrease from the prior period — about 8.7 days to cover at its recent average daily volume. On November 20, 2026, 22.2% of COGT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for COGT, detected from its recent SEC filings · based on capital-structure filings through 2026-08-10.
$400M ATM Prospectus Supplement Filed · Potential Dilution of ~5.6%
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →